Selected research
Market Structure
Global Antibody Drug CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Antibody Drug CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Antibody Drug CDMO Service include Abzena, AGC Biologics, Axplora, Batavia Biosciences, ChemExpress, FUJIFILM, GTP Bioways, Halix and MYCENAX, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Antibody Drug CDMO Service market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Antibody Drug CDMO Service and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Antibody Drug CDMO Service revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Antibody Drug CDMO Service market size, projected growth trends, production technologies, key applications, and end-use industries.
Antibody Drug CDMO Service Segment by Company
Abzena
AGC Biologics
Axplora
Batavia Biosciences
ChemExpress
FUJIFILM
GTP Bioways
Halix
MYCENAX
WuXi Biologics
ProBio
Samsung Biologics
Sigma-Aldrich
Antibody Drug CDMO Service Segment by Type
Customized Service
Lab-based Service
Others
Antibody Drug CDMO Service Segment by Application
Antibody Drug Conjugates
Monoclonal Antibodies
Others
Antibody Drug CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Antibody Drug CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody Drug CDMO Service industry.
Chapter 3: Detailed analysis of Antibody Drug CDMO Service companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug CDMO Servicerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Customized Service
- Lab-based Service
- Others
Applications
- Antibody Drug Conjugates
- Monoclonal Antibodies
- Others
Companies covered
- Abzena
- AGC Biologics
- Axplora
- Batavia Biosciences
- ChemExpress
- FUJIFILM
- GTP Bioways
- Halix
- MYCENAX
- WuXi Biologics
- ProBio
- Samsung Biologics
- Sigma-Aldrich
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Antibody Drug CDMO Service Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Customized Service
- 1.2.3 Lab-based Service
- 1.2.4 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Antibody Drug CDMO Service Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Antibody Drug Conjugates
- 1.3.3 Monoclonal Antibodies
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Antibody Drug CDMO Service Growth Trends by Region
- 1.5.1 Global Antibody Drug CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Antibody Drug CDMO Service Market Size by Region (2021-2026)
- 1.5.3 Antibody Drug CDMO Service Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Antibody Drug CDMO Service Market Dynamics
- 2.1 Antibody Drug CDMO Service Industry Trends
- 2.2 Antibody Drug CDMO Service Industry Drivers
- 2.3 Antibody Drug CDMO Service Industry Opportunities and Challenges
- 2.4 Antibody Drug CDMO Service Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Antibody Drug CDMO Service Revenue by Company (2021-2026)
- 3.2 Global Antibody Drug CDMO Service Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Antibody Drug CDMO Service Key Company Head office and Area Served
- 3.4 Global Antibody Drug CDMO Service Company, Product Type & Application
- 3.5 Global Antibody Drug CDMO Service Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Antibody Drug CDMO Service Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Antibody Drug CDMO Service Players Market Share by Revenue in 2025
- 3.6.3 2025 Antibody Drug CDMO Service Tier 1, Tier 2, and Tier 3
4 Antibody Drug CDMO Service Market by Type
- 4.1 Global Antibody Drug CDMO Service Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Antibody Drug CDMO Service Market Size by Type (2021-2032)
- 4.3 Global Antibody Drug CDMO Service Market Size Share by Type (2021-2032)
5 Antibody Drug CDMO Service Market by Application
- 5.1 Global Antibody Drug CDMO Service Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Antibody Drug CDMO Service Market Size by Application (2021-2032)
- 5.3 Global Antibody Drug CDMO Service Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Abzena
- 6.1.1 Abzena Company Information
- 6.1.2 Abzena Business Overview
- 6.1.3 Abzena Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Abzena Antibody Drug CDMO Service Product Portfolio
- 6.1.5 Abzena Recent Developments
- 6.2 AGC Biologics
- 6.2.1 AGC Biologics Company Information
- 6.2.2 AGC Biologics Business Overview
- 6.2.3 AGC Biologics Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 AGC Biologics Antibody Drug CDMO Service Product Portfolio
- 6.2.5 AGC Biologics Recent Developments
- 6.3 Axplora
- 6.3.1 Axplora Company Information
- 6.3.2 Axplora Business Overview
- 6.3.3 Axplora Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Axplora Antibody Drug CDMO Service Product Portfolio
- 6.3.5 Axplora Recent Developments
- 6.4 Batavia Biosciences
- 6.4.1 Batavia Biosciences Company Information
- 6.4.2 Batavia Biosciences Business Overview
- 6.4.3 Batavia Biosciences Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Batavia Biosciences Antibody Drug CDMO Service Product Portfolio
- 6.4.5 Batavia Biosciences Recent Developments
- 6.5 ChemExpress
- 6.5.1 ChemExpress Company Information
- 6.5.2 ChemExpress Business Overview
- 6.5.3 ChemExpress Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 ChemExpress Antibody Drug CDMO Service Product Portfolio
- 6.5.5 ChemExpress Recent Developments
- 6.6 FUJIFILM
- 6.6.1 FUJIFILM Company Information
- 6.6.2 FUJIFILM Business Overview
- 6.6.3 FUJIFILM Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 FUJIFILM Antibody Drug CDMO Service Product Portfolio
- 6.6.5 FUJIFILM Recent Developments
- 6.7 GTP Bioways
- 6.7.1 GTP Bioways Company Information
- 6.7.2 GTP Bioways Business Overview
- 6.7.3 GTP Bioways Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 GTP Bioways Antibody Drug CDMO Service Product Portfolio
- 6.7.5 GTP Bioways Recent Developments
- 6.8 Halix
- 6.8.1 Halix Company Information
- 6.8.2 Halix Business Overview
- 6.8.3 Halix Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Halix Antibody Drug CDMO Service Product Portfolio
- 6.8.5 Halix Recent Developments
- 6.9 MYCENAX
- 6.9.1 MYCENAX Company Information
- 6.9.2 MYCENAX Business Overview
- 6.9.3 MYCENAX Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 MYCENAX Antibody Drug CDMO Service Product Portfolio
- 6.9.5 MYCENAX Recent Developments
- 6.10 WuXi Biologics
- 6.10.1 WuXi Biologics Company Information
- 6.10.2 WuXi Biologics Business Overview
- 6.10.3 WuXi Biologics Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 WuXi Biologics Antibody Drug CDMO Service Product Portfolio
- 6.10.5 WuXi Biologics Recent Developments
- 6.11 ProBio
- 6.11.1 ProBio Company Information
- 6.11.2 ProBio Business Overview
- 6.11.3 ProBio Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 ProBio Antibody Drug CDMO Service Product Portfolio
- 6.11.5 ProBio Recent Developments
- 6.12 Samsung Biologics
- 6.12.1 Samsung Biologics Company Information
- 6.12.2 Samsung Biologics Business Overview
- 6.12.3 Samsung Biologics Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Samsung Biologics Antibody Drug CDMO Service Product Portfolio
- 6.12.5 Samsung Biologics Recent Developments
- 6.13 Sigma-Aldrich
- 6.13.1 Sigma-Aldrich Company Information
- 6.13.2 Sigma-Aldrich Business Overview
- 6.13.3 Sigma-Aldrich Antibody Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Sigma-Aldrich Antibody Drug CDMO Service Product Portfolio
- 6.13.5 Sigma-Aldrich Recent Developments
7 North America
- 7.1 North America Antibody Drug CDMO Service Market Size (2021-2032)
- 7.2 North America Antibody Drug CDMO Service Market Size by Type
- 7.2.1 North America Antibody Drug CDMO Service Market Size by Type (2021-2026)
- 7.2.2 North America Antibody Drug CDMO Service Market Size by Type (2027-2032)
- 7.2.3 North America Antibody Drug CDMO Service Market Share by Type (2021-2032)
- 7.3 North America Antibody Drug CDMO Service Market Size by Application
- 7.3.1 North America Antibody Drug CDMO Service Market Size by Application (2021-2026)
- 7.3.2 North America Antibody Drug CDMO Service Market Size by Application (2027-2032)
- 7.3.3 North America Antibody Drug CDMO Service Market Share by Application (2021-2032)
- 7.4 North America Antibody Drug CDMO Service Market Size by Country
- 7.4.1 North America Antibody Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 7.4.3 North America Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 7.4.4 North America Antibody Drug CDMO Service Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Antibody Drug CDMO Service Market Size (2021-2032)
- 8.2 Europe Antibody Drug CDMO Service Market Size by Type
- 8.2.1 Europe Antibody Drug CDMO Service Market Size by Type (2021-2026)
- 8.2.2 Europe Antibody Drug CDMO Service Market Size by Type (2027-2032)
- 8.2.3 Europe Antibody Drug CDMO Service Market Share by Type (2021-2032)
- 8.3 Europe Antibody Drug CDMO Service Market Size by Application
- 8.3.1 Europe Antibody Drug CDMO Service Market Size by Application (2021-2026)
- 8.3.2 Europe Antibody Drug CDMO Service Market Size by Application (2027-2032)
- 8.3.3 Europe Antibody Drug CDMO Service Market Share by Application (2021-2032)
- 8.4 Europe Antibody Drug CDMO Service Market Size by Country
- 8.4.1 Europe Antibody Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 8.4.3 Europe Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 8.4.4 Europe Antibody Drug CDMO Service Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Antibody Drug CDMO Service Market Size (2021-2032)
- 9.2 China Antibody Drug CDMO Service Market Size by Type
- 9.2.1 China Antibody Drug CDMO Service Market Size by Type (2021-2026)
- 9.2.2 China Antibody Drug CDMO Service Market Size by Type (2027-2032)
- 9.2.3 China Antibody Drug CDMO Service Market Share by Type (2021-2032)
- 9.3 China Antibody Drug CDMO Service Market Size by Application
- 9.3.1 China Antibody Drug CDMO Service Market Size by Application (2021-2026)
- 9.3.2 China Antibody Drug CDMO Service Market Size by Application (2027-2032)
- 9.3.3 China Antibody Drug CDMO Service Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Antibody Drug CDMO Service Market Size (2021-2032)
- 10.2 Asia Antibody Drug CDMO Service Market Size by Type
- 10.2.1 Asia Antibody Drug CDMO Service Market Size by Type (2021-2026)
- 10.2.2 Asia Antibody Drug CDMO Service Market Size by Type (2027-2032)
- 10.2.3 Asia Antibody Drug CDMO Service Market Share by Type (2021-2032)
- 10.3 Asia Antibody Drug CDMO Service Market Size by Application
- 10.3.1 Asia Antibody Drug CDMO Service Market Size by Application (2021-2026)
- 10.3.2 Asia Antibody Drug CDMO Service Market Size by Application (2027-2032)
- 10.3.3 Asia Antibody Drug CDMO Service Market Share by Application (2021-2032)
- 10.4 Asia Antibody Drug CDMO Service Market Size by Country
- 10.4.1 Asia Antibody Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 10.4.3 Asia Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 10.4.4 Asia Antibody Drug CDMO Service Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Antibody Drug CDMO Service Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Type
- 11.2.1 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Antibody Drug CDMO Service Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Application
- 11.3.1 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Antibody Drug CDMO Service Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Country
- 11.4.1 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Antibody Drug CDMO Service Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Antibody Drug CDMO Service Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst